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Abstract 
Anti-transgene immune responses elicited after intramuscular (IM) delivery of 
recombinant Adeno-Associated Viruses (rAAV) have been shown to hamper long-term 
transgene expression in large animal models of rAAV-mediated gene transfer. To 
overcome this hurdle, we and others described an alternative mode of delivery of rAAV 
vectors in nonhuman primate muscles: the locoregional intravenous route of 
administration (LR). Using this injection mode, we previously reported in cynomolgus 
monkeys a persistent inducible transgene expression for at least 1 year under the control 
of the tetracycline-inducible TetON system, with no immunity against the rtTA transgene 
product. The present study shows the long-term follow-up of these animals. We report 
that LR delivery of a rAAV2/1 vector allows long term inducible expression up to at least 5 
years post-gene transfer with no any detectable host immune response against the 
transactivator rtTA despite its immunogenicity following IM gene transfer. This study 
shows for the first time a long-term regulation of muscle gene expression using TetON-
inducible system in a large animal model. Moreover, these findings further confirm that 
rAAV LR delivery route is efficient and immunologically safe, allowing long-term skeletal 
muscle gene transfer. 
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INTRODUCTION 
Over the last decade, recombinant Adeno-Associated Virus (rAAV)-based gene therapies 
have shown great promises for the treatment of genetic disorders, with numerous studies 
evolving from proof-of- concepts to clinical trials or even Marketing Authorization 
Application (MAA) in Europe or Biologic Licence Application (BLA) in US 1–4. Nevertheless, 
immune responses directed against the vector capsid or the transgene product remain 
potential limiting factors to long-term gene transfer efficiency, even though their impact 
on transgene expression can be difficult to understand 5–7. For several years, we’ve been 
taken particular interest in the impact of anti-transgene immune responses triggered after 
muscle-directed rAAV-mediated gene transfer 8–10. Skeletal muscle is the target tissue of 
choice for gene therapy of numerous neuromuscular diseases and metabolic disorders 11. 
In the context of rAAV-mediated gene transfer, muscle-directed gene therapy strategies 
have first relied on the direct intramuscular (IM) delivery of the viral vector. Indeed, this 
administration route is non-invasive, easily transposable into clinic, and long-term 
transgene expression has been obtained upon IM delivery of rAAV in large animal models 
as well as in humans 8,11–14. However, in large animal models, numerous cases of immune 
responses directed against the transgene product have been reported, all leading to the 
loss of transgene expression that can be attributed to the activation of transgene-specific 
CD8+ T lymphocytes 8,15–17. In clinical trials, the limited number of available data seems to 
indicate that the impact of anti-transgene immune responses on rAAV-mediated gene 
transfer efficiency is not as predictive as animal models led us to expect 13,18. Indeed, their 
occurrence seems not to be systematically correlated to the loss of transgene expression, 
although consensual conclusions are hard to draw considering the wide diversity of clinical 
settings (pathological state and pre-medication of the patients, immunosuppressive 
regimens administered before or during clinical trials, genetics and vector dosing) 19. In 
addition, in the majority of trials, patients with null mutations and/or a high risk of 
transgene rejection were generally excluded. 
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Several key features of rAAV-mediated gene transfer, likely to influence the occurrence of 
immune responses directed against the transgene product, have now been identified. 
Among which, we find the vector serotype, the dose, the genome conformation, the 
immunogenicity of the transgene product and the route of vector administration 20. In an 
effort to circumvent the risks of anti-transgene immune responses following rAAV IM 
delivery, and to allow the transduction of larger muscle territories upon a single injection 
of an rAAV vector, we and others have developed an alternative mode of muscle-directed 
vector administration: the locoregional intravenous (LR) route 10,21–24. The LR 
administration route has shown in large animal models (dogs and non-human primates 
(NHP)) that, on top of being well tolerated, it allows a more diffused transgene expression 
in all muscles of the perfused limb (when compared to IM administration), thanks to an 
increased extravasation of vector particles into the muscles. We also previously reported a 
persisting gene transfer (for at least one year post-perfusion) after LR delivery of an 
rAAV2/1 vector expressing an inducible Epo reporter gene under the control of the TetON 
system that is based on the expression of the rtTA transactivator. This persisting gene 
regulation was observed in the absence of any immunosuppressive regimen in all 3 
cynomolgus monkeys, whereas transgene expression did not exceed 3 months in IM-
injected NHPs 10. Additionally, although we observed anti-AAV2/1 directed antibodies in 
these LR-injected animals, we did not detect any humoral response directed toward the 
transgene product or cellular infiltrates in muscle biopsies. 
In the present study, we document the long-term follow-up of these 3 LR-perfused NHPs 
over a period of 5 years. We characterized vector biodistribution and level of transgene 
expression, as well as the state of anti-transgene immune responses during this extended 
period. In all animals, we observed a persistent and stable TetON inducible transgene 
expression in the muscles of the perfused limb for at least 5 years post-rAAV2/1 LR 
injection. This persisting transgene expression wasn’t associated with any humoral or 
cellular responses directed against the rtTA transgene product, neither in the periphery 
nor in the perfused muscles with no cellular infiltrates. To our knowledge, this is the first 
time that the TetON inducible system was proven to be efficient over a long period of time 
in a large animal model of muscle gene transfer. In previous studies, the TetON rtTA-based 
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system was systematically rejected by the host immune system when the vector was 
administered to the muscle or systemically,  with a rapid loss of inducible gene expression 
8,25–27. Our findings strongly suggest that LR delivery of rAAV vectors is efficient and 
immunologically safe, in contrast to IM injection. It confirms the critical impact of vector 
mode of delivery on host immunity. 
MATERIALS AND METHODS 
A large part of this work was performed under the control of a quality management 
system that is approved by Lloyd's Register Quality Assurance LRQA to meet the 
requirements of international Management System Standards ISO 9001:2008. It has been 
implemented to cover all activities in the laboratory including research experiments and 
production of research-grade viral vectors. 
Vector Production 
Recombinant AAV2/ vector was produced as described in Toromanoff et al. 10. 
Animal care and welfare 
Nonhuman primates (Macaca Fascicularis) were maintained for experimentation after 
approval of the Institutional Animal Care and Use Committee of the University of Nantes, 
and under the supervision of a Doctor of Veterinary Medicine Degree (DVM). Special 
attention was paid to the health and welfare of animals. Blood samples were collected 
regularly to follow biochemical and hematological parameters, in conformity with 
physiological guidelines. More precisely, primates were anesthetized with intramuscular 
injection of 20 μg/kg medetomidine (Domitor®; Pfizer, Paris, France) associated to 8 mg/kg 
of ketamine (Imalgène®; Rhone Merieux, Toulouse, France). For each Epo protein 
expression induction, 20, 10 and 10 mg/kg of doxycycline (ELERTE, France) were 
administrated per os at day 1, 2 and 3 respectively. At the end of the protocol, euthanasia 
was performed with intravenous injection of sodium pentobarbital (Dolethal®, Vétoquinol, 
France) after 0.1 mg/kg morphine-induced analgesia. 
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Analysis of secreted Erythropoietin 
As described in our previous studies 8,10,25, serum cynomolgus Epo protein levels were 
measured by enzyme-linked immunosorbent assay (Quantikine IVD kit, R&D system) 
according to manufacturer’s procedures. Physiological variation levels of serum Epo 
protein were obtained from titration of a total of 182 serum samples obtained from 32 
different NHP and calculated as follow: mean of Epo protein level + 2*Standard Deviations.  
Quantitative real-time PCR analysis  
Total genomic DNA from total tissues was extracted using the Gentra Puregene kit 
(Qiagen) and Tissue Lyser II (Qiagen) according to manufacturers’ procedures. Total RNA 
was obtained from lysis of tissues by Tissue Lyser II and using TRIzol (Thermo) and 
chloroform (Sigma)-based extraction. Total RNA was then treated with RNAse-free DNAse I 
from the TURBO DNA-freeTM kit (Thermo) to eliminate DNA contamination. 500 ng of RNA 
were reverse transcribed using the M-MLV reverse-transcriptase kit (Thermo). Vector 
genome DNA and transgene cDNA were measured through quantification of Bovine 
Growth Hormone polyadenylation signal (BGH-pA) localized downstream the rtTA 
sequence 25 using a StepOne Plus instrument (Thermo). The primers and TaqMan probe 
used are: forward primer 5’-TCTAGTTGCCAGCCATCTGTTGT-3’ ; reverse primer 5’-
TGGGAGTGGCACCTTCCA-3’ and BGH-pA probe 5’(6 FAM)- TCCCCCGTGCCTTCCTTGACC-3’ 
TAMRA. The BGH-pA quantitative PCR was done using the following program: initial 
denaturation 20 sec at 95°C followed by 45 cycles of 1 sec at 95°C and 20 sec at 60°C. 
For vector genome quantification, data were normalized by quantifying the endogenous 
NHP ε -globin DNA using the following primers: forward primer: 5’-
ACATAGCTTGCTTCAGAACGGT-3’ ; reverse primer : 5’-AGTGTCTTCATCCTGCCCTAAA-3’ and 
ε-globin probe: 5’ (6 FAM)-TGCAGGCTGCCTGGCAGAAGC-3’ TAMRA. The ε-globin 
quantitative PCR was performed with the program: initial denaturation 20 sec at 95°C 
followed by 45 cycles of 3 sec at 90°C and 30 sec at 60°C. For each sample, Ct values were 
compared with those obtained with plasmid (containing either the BGH-pA sequence or 
the ε-globin sequence) standard dilutions. 
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The reverse-transcribed mRNA measurement were normalized by quantifying the 
endogenous NHP HPRT1 reverse transcribed mRNA, using the following primers to target 
the HPRT1 sequence: forward primer 5’- GCTTTCCTTGGTCAGGCAGTA-3’ ; reverse primer 
5’-TGGAGTCCTTTTCACCAGCA-3’ ; and HPRT1 probe 5’ (6 FAM) 
AATCCAAAGATGGTCAAGGTCGCAA-3’ TAMRA. The HPRT1 quantitative PCR was done using 
the following program: initial denaturation 20 sec at 95°C followed by 40 cycles of 3 sec at 
95°C and 30 sec at 62°C. The Ct results obtained for the transgene and transcripts were 
normalized with HPRT values using RQ=2-ΔCt. 
Follow-up of anti-TetR humoral immune responses 
Detection of serum anti-rtTA antibodies was conducted using an enzyme-linked 
immunosorbent assay (ELISA) as previously described 28. Briefly, Nunc MaxiSorp P96 plates 
(Sigma) were coated with recombinant rtTA protein (5μg/mL, Proteogenix). After washing 
steps and saturation, sera were added in each well at various dilutions (twofold dilutions 
from 1/10 to 1/20480) and incubated 2 hours at 37°C. Following 1 hours at 37°C incubation 
of (HRP)-conjugated anti-rhesus IgG (Cliniscience), revelation was performed using 2.2-
3,3',5,5'-Tetramethylbenzidine (TMB, BD OptEIA, BD Biosciences). Absorbances of 
duplicate samples were read at 450 nm with a correction at 570 nm on a Multiskan Go 
reader (Thermo Scientific). Threshold of positivity was determined using 21 negative sera 
obtained from naïve NHPs as mean of optic density for each dilution + 2*SD. IgG titers for 
experimental animals were defined as the last serum dilution whose optic density 
remained above the threshold. 
Follow-up of anti-TetR cellular immune responses 
The anti-TetR Immune cellular response was evaluated with an IFNγ ELISpot assay as 
previously described 28. Briefly, 2E5 thawed PBMC were stimulated with 5 rtTA peptides 
pools covering the rtTA sequence (overlapping peptide library 15 per 10 mers, Sigma) into 
human anti-IFNγ (MabTech, France) pre-coated polyvinylidene difluoridemembrane 
(PVDF) MultiScreen®HTS filter plates (Millipore). Positive and negative controls were 
obtained using Concanavalin A (Sigma) or medium alone, respectively. After incubation 
with a biotinylated anti-IFNγ antibody (clone 7-B6- 1, MabTech, France) and 
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ExtrAvidin®Alkalin Phosphatase (Sigma- Aldrich, France), enzymatic reaction was revealed 
using NBT/BCIP (Thermo). Spot number was determined using an ELISpot reader ELR07 
(AID, Germany) and analyzed with AID ELISpot Reader Software V7.0. Responses were 
considered positive when the number of spot-forming colonies (SFC) per million cells were 
>50 and at least 3-fold higher than the negative control (C-). The rtTA-immunized macaque 
was obtained by the administration of the same vector rAAV1-rtTA/Epo combined with 2 
intradermal injections of rtTA-pulsed dendritic cells as published in Moreau et al. 28. 
Follow-up of anti-AAV2/1 humoral immune responses 
Detection of serum anti-AAV2/1 antibodies was conducted using an enzyme-linked 
immunosorbent assay (ELISA). Nunc MaxiSorp P96 plates (Sigma) were coated with 1E9 
vg/well of recombinant AAV2/1 rtTA-Epo. Following saturation, sera were added in wells at 
various dilutions (twofold dilutions from 1/10 to 1/40960) and incubated 2 hours. A 
biotinylated anti human IgG (Jackson Immunoresearch, USA) was incubated for 1 hour at 
37°C followed by a horseradish peroxidase (HRP)-conjugated Streptavidin (Vector, USA). 
Finally, revelation was performed using 2.2-3,3',5,5'-Tetramethylbenzidine (TMB, BD 
OptEIA, BD Biosciences) and absorbance of duplicate samples were read at 450 nm with a 
correction at 570 nm on a Multiskan Go reader (Thermo Scientific). As for rtTA, threshold 
of positivity was determined using 14 negative sera obtained from naïve NHPs as mean of 
optic density for each dilution + 2*SD. IgG titers for experimental animals were defined as 
the last sera dilution whose optic density remained above the threshold curve. 
Follow-up of anti-AAV1 Neutralizing Factors 
Two hours prior to rAAV transduction, a permissive cell line was infected with wild-type 
Adenovirus serotype 5. During this incubation time, a rAAV2/1 expressing the reporter 
gene LacZ (encoding beta-galactosidase) was incubated with diluted serum and the mix 
was added to the cell line. 24 hours later, the cells were fixed with 0.5% of Glutaraldéhyde 
(Sigma) and stained with X-gal solution (Promega). The transduction was determined by 
light microscopy. The titer of neutralizing factors was defined as the last dilution that 
inhibits the transduction as compared to the transduction control (without serum).  
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Histopathological analysis 
Muscles were sampled at euthanasia more than 5 years post-injection. Hematoxylin-
phloxine-saffron staining (HPS) was performed as per standard histological protocols using 
formol-fixed and paraffine-embedded muscle sections. The slides were observed using a 
NanoZoomer Slide Scanner (Hamamatsu). 
RESULTS 
Persisting expression of an inducible transgene 5 years after locoregional delivery of 
rAAV2/1. 
Three NHPs (Mac 19, 20 and 21) were LR-perfused with 1E11 vg/kg of rAAV2/1 rtTA/Epo. 
Doxycycline was then administered periodically to induce the rtTA-mediated 
transactivation of the Tet-O-CMV promoter, and subsequently the expression of the 
Erythropoietin (Epo) protein 8,10,24,25. Epo protein secretion in the serum was measured by 
ELISA during the 21 days after every doxycycline administration cycle. Our previous results 
showed a persisting Epo transgene expression, with a secretion peak of recombinant Epo 
protein in the serum following every doxycycline administration, during one year after LR 
delivery of rAAV2/1, without any immune suppression 10. Moreover, although the rtTA 
transactivator was permanently expressed (under the control of the Desmin promoter), we 
did not detect any immune response against this immunogenic foreign protein in any of 
the three LR-injected NHP, as opposed to IM-injected NHP 10. 
Here, we extended the follow-up of the three LR-perfused animals over a period of 5 years 
(Table 1 and Figure 1). Interestingly, all three animals still exhibited a peak of Epo protein 
secretion in the serum after each doxycycline induction, which was systematically 
correlated with an increase of the levels of circulating reticulocytes (Supplementary Fig.1). 
However, we noticed a slight decrease of Epo protein levels in the serum after the 7th 
month post-perfusion: Epo peak expression was 1.3 to 2.6 fold lower than after the first 6 
inductions. This level then stabilized until the end of the protocol. Nonetheless, despite 
this decrease, each Epo protein peak was higher than physiologic variations of intrinsic Epo 
protein (Figure 1). These results demonstrate for the first time a persistent inducible 
transgene expression up to 5 years after LR delivery of AAV in non-human primates.  
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Most of vector genomes and transgene transcripts are localized in perfused muscles 5 
years after locoregional delivery. 
Vector biodistribution was evaluated by measuring viral vector genomes and 
constitutively-expressed rtTA transcripts through quantitative PCR and Reverse 
Transcriptase quantitative PCR, respectively. Quantifications were performed in 4 muscles 
of the perfused limb (biceps femoris, tibialis anterior, gastrocnemius medialis and 
gastrocnemius lateralis), in the same muscles of the contralateral limb, in distant muscles 
(biceps brachialis and brachioradialis), and in various organs (diaphragm, heart, liver and 
spleen). At 5 years post-infusion, most of the vector genomes (up to 0.08 vg/dg) were 
detected in perfused muscles and in the liver (Figure 2A). Only Mac 21 had detectable, 
though rare (less than 0.007 vg/dg), copies of vector genomes in contralateral or distant 
muscles.  
Related to these results, rtTA transcripts were mostly detected in perfused muscles (most 
of RQ comprises between 0.0264 and 0.3843) and not or few transcripts were detected in 
contralateral/distant muscles as well as in others organs as heart, diaphragm or spleen 
with RQ values always below the limit of PCR quantification (Figure 2B). We also detected 
rtTA transcripts in liver of the three NHP, though to a lesser degree than in perfused 
muscles (RQ = 0.0058, 0.0076 and 0.0340 for Mac 19, 20 and 21 respectively). Overall, 
these data indicate that the transgene is essentially found and expressed in the muscles of 
the perfused limb, with low to no expression at distant sites, except in the liver. 
Monitoring humoral and cellular immune responses 
We have observed a slight decrease in Epo protein secretion 7 months post-LR infusion of 
rAAV2/1 vectors. To investigate whether this could be attributed to a transient immune 
response targeting transduced cells, we monitored anti-transgene humoral and cellular 
responses in the periphery. We first investigated the kinetics of serum anti-rtTA humoral 
immune using an ELISA assay at 15 days, 3 months, 10 months, 2.5 years and 5 years post-
gene transfer. As shown in Table 1 and Table 2, we couldn’t detect any anti-rtTA IgG 
antibodies at any time during the protocol. In the same manner, anti-rtTA T-cell responses 
were assessed at 5 year post-injection on PBMCs stimulated with rtTA peptide pools 
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through an IFN-γ ELISpot assay (Table 1 and Figure 3). We did not detect any IFN-γ 
secretion at 5 year post-perfusion in contrast to an rtTA-immunized macaque. Overall, 
these results indicate that LR administration did not induce any detectable anti-transgene 
immune response at least at the time points analyzed in this study. 
To complete vector immunogenicity assessment, we evaluated AAV2/1 humoral response 
by determining anti-AAV2/1 IgG antibody titers in the serum using an ELISA assay at 
various time-points over 5 years (Table 1 and Table 2). For all three NHPs, serum anti-
AAV2/1 antibodies occurred from day 15 post-perfusion onward, peaking between 3 and 
10 months, with titers ranging from 1/5120 to 1/10240. Afterwards, anti-AAV2/1 IgG 
antibody amounts tended to decrease slowly over time but remained relatively high for 
two NHPs at 5 years post-perfusion (1/5120 and 1/1280 for Mac 19 and Mac 21 
respectively). 
Anti-AAV2/1 IgG antibodies were associated with the induction of anti-AAV2/1 neutralizing 
factors in the serum. Neutralizing factors were detected from month 3 post-perfusion 
onward, with titers ranging from 1/1000 to 1/5000. As for anti-AAV2/1 IgG antibodies, 
neutralizing factor titers decreased over time but remained relatively high at 5 years post-
perfusion (1/100 and 1/1000) (Table 1 and Table 2). These results indicate that LR 
administration induced a long-term anti-AAV2/1 humoral response, which tends to 
gradually decrease over time. 
Absence of infiltrating immune cells in muscles 5 years after locoregional delivery 
To deepen our analysis of anti-transgene cellular response after LR delivery, we 
investigated the potential infiltration of immune cells in perfused muscles. Therefore, we 
performed Hematoxylin-phloxine-saffron (HPS) staining on four muscle sections from the 
injected limb (gastrocnemius lateralis, tibialis anterior, gastrocnemius medialis and biceps 
femoris) and one muscle section from the contralateral limb (tibialis anterior) obtained at 
sacrifice, 5 years after vector delivery (Table 1 and Figure 4 for representative sections). No 
infiltrated immune cells were detected in any of the muscle sections analyzed at 5 years 
post-LR infusion.  
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DISCUSSION 
Gene therapy using rAAV has grown by leaps and bounds among the past decade, 
culminating with the first EMA-approved product Glybera delivered in 2012 to treat 
lipoprotein lipase deficiency 1,3. Since then, another rAAV gene therapy product has been 
approved at the end of 2017 by the FDA for a genetic retinal dystrophy 3,4. Pre-clinical 
studies in large animal models have largely contributed to these successful developments, 
although few of them provide insights on the long-term efficiency and stability of rAAV-
mediated gene transfer. The highest number of long term reports (between 2.5 and 6 
years post-injection) have been provided for gene transfer studies targeting retinal 
immune privileged site and the central nervous system in NHP and canine models 29–31. 
When it concerns systemic, intramuscular or intrahepatic routes, there are now also 
numerous promising long term reports (between 2 and 8 years post-injection) in NHP 32 
and canine models for diabetes 33, metabolic diseases 34, hemophilia 35,36 or muscular 
dystrophies 37,38. Moreover, the field has now the benefit of up to 10 years hindsight in 
humans with persisting gene transfer following 1 single injection 39–42. All these studies 
highlight the tremendous achievements of rAAV-based gene therapy. 
When it concerns rAAV-mediated gene transfer to the skeletal muscle, IM-based strategies 
were first described and have shown long term efficient gene transfer when host effector 
immunity is not triggered. This was achieved in large animal models 8,10,33, and even up to 
5 and 10 years, in phase I/II clinical trials for alpha-anti-trypsin deficiency 43, and 
hemophilia B 40, respectively. However, IM route generally requires multiple sites of 
injection to achieve sufficient amounts of gene expression with a wider distribution, which 
in turns could increase the risk of gene transfer immunogenicity as described in multiple 
studies 8,10–13,15,25,45,46. There is clear evidence that the vector dose per IM site is a major 
determinant of unwanted immune responses to the transgene as shown for instance for 
FIX in hemophilia B dogs 47. 
LR mode of delivery was described as a promising alternative to overcome limited gene 
transfer efficiency following IM vector delivery and associated potential immunogenicity 
towards the transgene product. We and others have indeed shown that LR-based gene 
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transfer allows persisting gene transfer in larger muscle territories of the perfused limb 
using NHP or canine models 10,22–24,38,48. 
In the present study, we followed-up three NHPs over, to our knowledge the longest 
follow-up (a 5-year time course), following a LR perfusion of an AAV vector. Inducible Epo 
transgene expression over time was measured in serum by ELISA and revealed a 
systematic peak of expression after each doxycycline induction phase, which evidenced for 
the first time the ability of rAAV2/1-LR administration to sustain long-term TetON-
mediated inducible transgene expression in the NHP model, not only for one year, but also 
for at least 5 years, in the absence of any immunosuppressive treatment.  
Biodistribution analyses at 5 years post-perfusion showed that most of vector genomes are 
confined to perfused muscles and to the liver, confirming our previous results wherein 
most of transgene copies were found in the injected limb after LR delivery of rAAV2/1 or 
rAAV2/8 in NHPs 24 and rAAV8 in Duchenne GRMD dogs 23,38. When, an important 
biodistribution of the vector to the liver was shown initially to be a particular feature of 
serotype 8 49, it is now admitted that other AAV serotypes including AAV1 are able to 
partially home to the liver even following IM injection 24,50.  
In parallel, rtTA transcript quantification validated that vector copies in perfused muscles 
are the main source of transgene expression. Whereas we detected transgene mRNA in 
perfused muscles, we also detected rtTA transcripts in the liver of the 3 NHPs. This event 
parallels the leak of the desmin promoter in the liver initially described by Toromanoff and 
colleagues in this model 10, and could be explained by the transduction of Hepatic Stellate 
Cells by rAAV2/1 where desmin protein is expressed 10,51.  
The long term follow-up of our animals highlighted that at 7 months post-injection, the 
level of Epo protein secretion in the serum decreased to approximatively half of the initial 
level for each NHP, and remained stable until the end of the protocol, a phenomenon 
already observed in previous studies 8,24,52–54. A moderate or partial silencing of the 
transgene, as described by Suzuki and colleagues for adenoviral vectors 55, might account 
for this partial loss. Nonetheless, the decrease of Epo inducible expression in our model 
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didn’t affect the subsequent rate of reticulocytes in blood that remained constant after 
each doxycycline induction step (Supplementary Fig. 1). 
Otherwise, another possibility to explain Epo expression decrease is a partial and 
transitory immune-mediated destruction of the genetically modified myofibers. To further 
understand this event, we explored capsid and transgene-directed immune responses. 
Concerning anti-transgene immune responses, we were not able to detect transgene-
directed antibodies at any time during the protocol, even at early time points. 
Nonetheless, these results are not in line with previous LR studies in Duchenne and 
hemophilia canine models where transgene-directed IgG antibodies were detected 22,38,48. 
However, in these studies, rAAV2 or rAAV8 serotypes were used instead of rAAV1, and 
vectors were administered at higher doses ranging from 1E12 to 1E13 vg/kg, instead of 
1E11 in the present study. Interestingly, persisting µdystrophin or FIX transgenes 
expression was anyways observed suggesting a particular humoral immunity. Concerning 
anti-transgene cellular response, we did not detect rtTA-directed IFN-γ secreting cells at 5 
years post-perfusion. Unfortunately, except at the end of the protocol, we did not collect 
PBMC at intermediate time points and a transitory anti-transgene cellular immune 
response cannot be excluded. On the other hand, this result is consistent with the previous 
LR studies in dogs 22,23,48. 
Regarding anti-capsid immunity and as expected, we were able to detect circulating IgG 
antibodies as well as neutralizing factors in all NHPs during the whole protocol. 
Neutralizing factors and anti-capsid antibodies titers reached high levels during the first 
year and, despite an important decrease, remained high even at 5 years post-injection, 
indicating a long term capsid immunization after rAAV2/1 delivery similar to the reports by 
others after IV administration of rAAV8 in dogs 32. Importantly , these events seem to have 
no effect on the persistence of transgene expression, consistent with previous 
observations in preclinical and clinical trials 13. We didn’t check the anti-capsid cellular 
response but the long term persistence of transgene expression indicates that even if a 
cellular anti-capsid response did occur, it did not completely abrogate transgene 
expression. 
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In addition, we did not detect any infiltrated cells in muscle sections at 5 year post-infusion 
and, what’s more, muscles didn’t show any evidence of past immune cells infiltration 
(observation of an anatomy pathology EMA-certified expert). In opposition to those 
findings, in situ infiltrated cells have been detected at 4 weeks and 6 months in muscles of 
dogs from Arruda et al. and Haurigot et al. LR-studies respectively 22,48. The presence of 
cell infiltrates does not systematically mean an effector immune response. Indeed, 
regulatory T cells (Tregs) and/or exhausted/anergic T cells were shown to potentially play a 
role in the modulation of anti-transgene or capsid immune responses following AAV-
mediated gene transfer 43,56–60. The involvement of Tregs in muscle local tolerance was 
reported in two phase I/II clinical trials for alpha anti-tryspin and lipoprotein lipase 
deficiencies and associated to persisting gene expression 43,57,60. In addition and regarding 
the transgene product, liver-directed gene transfer was shown to be associated to 
tolerance 61–63 via the induction of specific regulatory T cells 64. Although, in our study, our 
observations argue in favor of no cellular infiltration after LR injection or rAAV2/1 at least 
in this particular model of rAAV-mediated inducible gene transfer. 
Overall, our model suggests that LR delivery doesn’t elicit anti-transgene immune rejection 
with neither humoral, nor cellular immunity. Even at relatively low doses of vectors (1E11 
vg/kg), in our hands, IM injection of the same vector from various serotypes induced in the 
majority of animals  transgene directed immune-response 8,10,24,25,28. This study confirms 
that, when the immune system is not mobilized against the rtTA transactivator, the tetR-
regulatable system is able to support long-term inducible transgene expression following 
either IM or LR vector administration. 
Following LR delivery, we didn’t detect any adverse event both at clinical and biochemical 
levels (supplementary Table 1), whether at early10,24 or late time points. Our results, along 
with previous studies in large animal models 21–23,38, confirm the safety of this procedure of 
injection which has already been validated for the perfusion of leg muscles in dystrophic 
patients 65.  
Our past and present studies involving LR administration of rAAV2/1 without 
immunosuppression demonstrated that the LR mode of delivery allowed a diffused 
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transduction of large muscle territories within the perfused limb, with minor diffusion to 
other organs (except for the liver). The expression of an inducible transgene product was 
found stable at long term, over-ranging 5 years, without any detectable deleterious effect 
of immune responses or toxicity associated to the expression of a foreign and highly 
immunogenic protein (rtTA transactivator). Whether these observations remain true 
across various AAV serotypes, transgene products and high vector doses remain to be 
investigated. Interestingly and despite the induction of a humoral response against the 
transgene product, data from other previous studies has also shown safe and long term 
gene transfer following LR delivery 22,38,48. Altogether, this study along with previous 
reports, strongly support that LR route, in the same way as the conventional intravenous 
route currently used in clinics, is safe and efficient and promotes its potential use as an 
alternative to IM injection for muscle delivery, in particular in the context of metabolic 
diseases needing the secretion of a therapeutic factor. Moreover, this study further 
confirms the critical impact of vector mode of delivery on host immunity. 
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Table 1. Summary table of long-term transgene expression and host immunity at 5 years 
post-perfusion 
NHP 
Mode of 
vector 
delivery 
Transgene 
expression  
Anti-
AAV1 
Ab 
Anti-
AAV1 
NF 
Anti-
rtTA Ab 
rtTA 
directed 
IFNg 
Cellular 
response 
Muscle 
infiltrates 
Mac 
19 
LR Persisting + + - - - 
Mac 
20 
LR Persisting + + - - - 
Mac 
21 
LR Persisting + + - - - 
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Table 2. Kinetic of humoral Response (anti-rtTA, anti-AAV1 responses and anti-AAV1 
Neutralizing Factors) 
  Before inj 15 days pi
3 months 
pi 
10 
months pi
2,5 years 
pi 
5 years pi 
Mac 
19 
Anti-
AAV1 
Ab 
Negative 1/40 1/10240 1/10240 1/5120 1/5120 
Anti-
AAV1 
NF 
Negative 
ND 1/5000 ND ND 1/1000 
Anti-
rtTA 
Ab 
Negative Negative Negative Negative Negative Negative 
Mac 
20 
Anti-
AAV1 
Ab 
Negative 
1/80 1/5120 1/1280 1/320 1/80 
Anti-
AAV1 
NF 
Negative 
ND 1/1000 ND ND 1/100 
Anti-
rtTA 
Ab 
Negative Negative Negative Negative Negative Negative 
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Mac 
21 
Anti-
AAV1 
Ab 
Negative 
1/80 1/10240 1/10240 1/5120 1/1280 
Anti-
AAV1 
NF 
Negative 
ND 1/5000 ND ND 1/1000 
Anti-
rtTA 
Ab 
Negative Negative Negative Negative Negative Negative 
ND = Not Determined, Ab = Antibodies, NF = Neutralizing Factors 
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Guilbaud et al.,FIGURE LEGENDS 
 
Fig1. Long-term dox-mediated transgene regulation. Long term follow-up (5 years) of 
serum Epo level in 3 LR injected macaques (Mac 19, Mac 20 and Mac 21) 10. Dox 
administrations are indicated by dotted lines . The grey area illustrates the physiologic 
basal levels of Epo  (established as mean +/-2SD of 182 measures of Epo in serum samples 
obtained from 32 cynomolgus macaques) 
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Fig2. Detection of viral genomes and transgene transcripts. Tissue samples were collected 
during necropsy. For each panel, perfused muscles correspond to Biceps femoris, tibialis 
anterior, gastrocnemius medialis and gastrocnemius lateralis of the injected limb. 
Contralateral muscles correspond to the same muscles of the non-injected limb and 
distant muscles correspond to biceps brachialis and brachioradialis of the 2 anterior limbs. 
D, H, L and S correspond to Diaphragm, Heart, Liver and Spleen respectively. (A) Viral 
genomes were determined by quantitative PCR (qPCR) and expressed as viral genome per 
diploid genome (vg/dg). (B) Transcripts were detected by reverse-transcription and qPCR 
(RT-qPCR) and expressed as relative quantity (RQ) to an endogenous gene. The grey areas 
corresponds to the limit of quantification of PCR detection (0.000809 vg/dg for panel A 
and RQ of 0.00304 for panel B) 
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Fig3. No detection of anti-rtTA IFNγ T cell response at 5 years post-injection. PBMCs were 
collected at euthanasia (5 years post-injection) and secretion of IFNγ by rtTA-stimulated 
PBMCs was evaluated by ELISpot. Cells were stimulated using an overlapping 15 per 10 
amino-acids peptide library covering the rtTA protein and divided in 5 pools (p1 to p5). 
Negative controls (C-) consisted in PBMCs cultured with medium alone and positive control 
(C+) consisted in mitogenic Concanavalin A (Con A) stimulation. IFNγ was measured as Spot 
Forming Cells (SFC). Threshold of positivity (dotted line) consists in SFC > 50 spots and 3 
times the number of SFC obtained with negative control (C-). For positive responses, 
statistical analysis was performed using a DFR test, *** for P value ≤ 0,001, ** for P value ≤ 
0,01, * for P value ≤ 0,05. 
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Fig4. No detection of muscle lesions at 5 years post-injection. Perfused (tibialis anterior 
and gastrocnemius lateralis) and contralateral (tibialis anterior) muscles were collected at 
euthanasia (5 years post-injection). HPS stainings were performed on formol-fixed and 
paraffin-treated muscles sections. Pictures were representative of whole section and 
indicate no infiltration of immune cells or lesions in perfused muscles. Scale bar = 200 µm. 
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Supplementary Table 1. Follow up of biochemical parameters 
Biochemical 
parameter 
Time-point Mac 19 Mac 20 Mac 21 
C-Reactive 
Protein 
(mg/mL) 
D-30 < 4 < 4 < 4 
D4 < 4 < 4 < 4 
D14 25.2 8.9 < 3 
D446 <3 <3 <3 
Alkaline 
Phosphatase 
(U/L) 
D-30 581 837 681 
D4 461 869 765 
D14 443 791 722 
D446 583 558 519 
ALAT 
(U/L) 
D-30 33 53 23 
D4 58 67 35 
D14 43 58 36 
D446 32 60 32 
γ-GT 
(U/L) 
D-30 146 140 169 
D4 102 127 157 
D14 106 111 138 
D446 110 101 114 
Creatin 
Kinase (U/L) 
D-30 367 600 888 
D4 308 878 329 
D14 637 421 447 
D446 196 3928 869 
Creatinin 
(mg/L) 
D-30 6.3 6.1 6.6 
D4 6 5.6 5.8 
D14 5.4 6.2 6.4 
D446 9.2 8.7 8.7 
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Urea 
(g/L) 
D-30 0.4 0.4 0.4 
D4 0.3 0.4 0.4 
D14 0.3 0.3 0.4 
D446 0.3 0.34 0.37 
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Guilbaud et al., Supplementary file 
 
Supplementary Fig.1. Long-term induction of Reticulocytes in blood. Reticulocytes (Red 
blood cells precursors) were measured throughout the duration of the protocol. 
Monitoring of Blood parameters were performed by technical core facility of University 
Hospital of Nantes (CHU of Nantes). Doxycyclin administrations are indicated by dotted 
lines. Reticulocyte peaks are correlated with those of Epo. 
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